Prognostic Factors and Treatment Results of High-Grade Osteosarcoma in Norway: A Scope Beyond the 'Classical' Patient

Autor: Kjetil Berner, Kirsten Sundby Hall, Odd R. Monge, Harald Weedon-Fekjær, Olga Zaikova, Øyvind S. Bruland

Publikováno v: Sarcoma, Vol 2015 (2015)

Purpose. A retrospective study of prognostic factors and treatment outcome of osteosarcoma (OS) during modern chemotherapy era with focus on patients with primary metastatic disease, nonextremity localisation, or age >40 years (nonclassical OS). Meth

Externí odkaz: https://doaj.org/article/8520d81124f84e73819e11b5e28ac6c2

Denosumab in patients with giant-cell tumor of bone in Norway: results from a nationwide cohort

Autor: Olga Zaikova, Kirsten Sundby Hall, Odd R. Monge, Clement S. Trovik, Ayca Løndalen, Kjetil Boye, Heidi Knobel, Nina L. Jebsen

Publikováno v: Acta oncologica (Stockholm, Sweden). 56(3)

Denosumab is a relatively new treatment option for patients with giant-cell tumor of bone (GCTB). The purpose of this study was to report the results for patients treated in Norway.Patients treated with denosumab for GCTB were identified from the cli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bad2f45490263d0453ead20bc296d93
https://pubmed.ncbi.nlm.nih.gov/28105885

A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma

Autor: Alvaro Lassaletta, Joseph Rubino, Michael Nebozhyn, Kumudu Pathiraja, Zsuzanna Pápai, Brian Der-Hua Lu, Richard Gorlick, Darcy A. Hille, Najat C. Daw, Odd R. Monge, Keith M. Skubitz, Stefan S. Bielack, Cynthia E. Herzog, Mark Ayers, David J. Mauro, Erica Boldrini, Peter M. Anderson, Siu Long Yao

Publikováno v: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Pediatric Blood & Cancer

Background Robatumumab (19D12; MK-7454 otherwise known as SCH717454) is a fully human antibody that binds to and inhibits insulin-like growth factor receptor-1 (IGF-1R). This multiinstitutional study (P04720) determined the safety and clinical effica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff23f29cb2e441ba8c22ae025c90df5
https://hdl.handle.net/20.500.12530/26021

Three vs. 1 year of adjuvant imatinib (IM) for operable high-risk GIST : The second planned analysis of the randomized SSGXVIII/AIO trial

Autor: Giuliano Ramadori, Annette Reichardt, Daniel Pink, Salah-Eddin Al-Batran, Kirsten Sundby Hall, Raija Kallio, Justus Duyster, Petri Bono, Thor Alvegård, Bengt E. Nilsson, Peter Reichardt, Odd R. Monge, Eva Wardelmann, Sebastian Bauer, Mikael Eriksson, Jouni Junnila, Peter Hohenberger, Heikki Joensuu, Marcus Schlemmer

Publikováno v: Web of Science

10505 Background: Three years of adjuvant IM is recommended after surgery for patients (pts) with high-risk GIST with an IM-sensitive mutation. This recommendation is based on the findings from the SSGXVIII/AIO trial that compared 1 year (Arm A) to 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c21a24be6f5863599264c43c7de781b8
http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.10505

Chemotherapy in soft tissue sarcoma

Autor: Kirsten Sundby Hall, Odd R. Monge, Hans Strander, Tom Wiklund, Thor Alvegård, Gunnar Sæter, Jan-Olof Fernberg

Publikováno v: Acta Orthopaedica Scandinavica. 70:62-68

The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I). It evaluated the single agent adjuvant doxorubicin in a randomized setting in patients with high-grade STS. No improvement was no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1dad56f855fc2cbe60296d1c617b085
https://doi.org/10.1080/17453674.1999.11744826